Visfatin (PBEF/Nampt) is an adipocytokine that exerts pleiotropic effects within the human body, particularly affecting its metabolism and immunity. Visfatin was originally identified as being secreted by peripheral blood lymphocytes acting as a pre-B-cell colony-enhancing factor (PBEF). However, it was subsequently reported to be expressed in almost every tissue of the human body, with visceral fat deposits being the main source of visfatin. In addition to its secreted form, visfatin may also be found intracellularly where it functions as a nicotinamide phosphoribosyltransferase (Nampt). Visfatin maternal plasma concentrations increase during pregnancy, suggesting its important role in this complicated process. Alterations in visfatin level also take place in patients during pregnancy complications. This review focuses on the ones that most commonly occur in connection with visfatin: preterm labor, pre-eclampsia and gestational diabetes mellitus. The review aims to provide a better understanding of the role of visfatin during pregnancy and the causes of its alteration in maternal plasma, highlighting the potential use of visfatin as a diagnostic marker of pregnancy complications in the future.

• MeSH
• biologické markery krev   MeSH
• cytokiny krev   imunologie   MeSH
• gestační diabetes krev   imunologie   MeSH
• lidé MeSH
• nikotinamidfosforibosyltransferasa krev   imunologie   MeSH
• předčasná porodní činnost krev   imunologie   MeSH
• preeklampsie krev   imunologie   MeSH
• těhotenství MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH

• Publikační typ
• abstrakt z konference MeSH

OBJECTIVES: The aim of the study is to investigate differences in visfatin concentrations between mothers with term and preterm birth (PTB) and between mothers who delivered within seven days and after more than seven days following admission for PTB/preterm premature rupture of membranes (PPROMs). METHODS: Maternal peripheral blood and cord blood were collected from 56 mothers with PTB (31 with PPROM) and 71 mothers with term delivery (three with PPROM). RESULTS: Maternal visfatin concentration was significantly higher for given gestational age in PTBs compared to term deliveries (p = .021) and also in mothers who delivered within seven days after admission for PTB or PPROM, compared to those who delivered after more than seven days (p = .027; p = .039). Cord blood visfatin concentration was found to be decreased in preterm compared to term infants (p = .007). CONCLUSIONS: Visfatin in both maternal and fetal circulation may play an important role in the pathogenesis of PTB/PPROM and could be used to distinguish between women who will deliver in a short period of time after clinical presentation of PTB/PPROM and those who deliver later. Nevertheless, additional research is necessary in order to identify its direct involvement in PTB/PPROM.

• MeSH
• cytokiny krev   genetika   MeSH
• dospělí MeSH
• fetální krev chemie   MeSH
• genotyp MeSH
• jednonukleotidový polymorfismus MeSH
• lidé MeSH
• nikotinamidfosforibosyltransferasa krev   genetika   MeSH
• předčasný odtok plodové vody krev   genetika   MeSH
• předčasný porod krev   genetika   MeSH
• studie případů a kontrol MeSH
• těhotenství MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

OBJECTIVE: Visfatin, also known as pre-B cell colony-enhancing factor, was recently characterized as a potent pro-inflammatory mediator in rheumatoid arthritis (RA). The aim of this study was to determine the effect of B cell depletion with rituximab on serum visfatin levels in patients with active RA. METHODS: We evaluated 31 patients with RA starting rituximab therapy at baseline and after 16 and 24 weeks using disease activity score (DAS28). The control group consisted of 33 gender and age-matched healthy individuals. CD19(+) B cells were assessed by flow cytometry and serum levels of visfatin and B cell-activating factor of the TNF family (BAFF) were measured by ELISA at baseline and week 16. RESULTS: Total number of B cells correlated positively with serum visfatin levels (rs=0.417, P=0.025) and negatively with serum BAFF levels (rs=-0.486, P=0.008) at baseline. Serum visfatin levels were significantly higher in patients with RA compared with healthy controls (P=0.026), and significantly decreased (P=0.010), while BAFF increased (P<0.001), and both proteins became negatively correlated following treatment with rituximab (rs=-0.438, P=0.017). Visfatin levels did not correlate with the disease activity, but lack of change in the serum visfatin levels between baseline and week 16 predicted worsening disease activity between weeks 16 and 24 (rs=0.452, P=0.014). CONCLUSION: In patients with active RA, serum visfatin levels are related to the number of B cells rather than to disease activity and decrease in response to treatment with rituximab. Further studies are necessary to show if visfatin is a marker with predictive value for deterioration of RA.

• MeSH
• B-lymfocyty účinky léků   imunologie   MeSH
• demografie MeSH
• faktor aktivující B-buňky metabolismus   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lymfocytární deplece MeSH
• myší monoklonální protilátky farmakologie   terapeutické užití   MeSH
• nikotinamidfosforibosyltransferasa krev   MeSH
• počet lymfocytů MeSH
• prediktivní hodnota testů MeSH
• progrese nemoci MeSH
• revmatoidní artritida krev   farmakoterapie   imunologie   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Jedním z velkých problémů současné celosvětové populace je neustále se zvyšující výskyt obesity. Problém obesity spočívá zejména v doprovodných komplikacích, mezi které patří insulinová resistence a kardiovaskulární poruchy. Nedávno objevenou úlohou tukové tkáně je sekrece tkáňových hormonů – adipokinů, které se účastní řady regulačních pochodů. Jedním z adipokinů je visfatin, který byl popsán v roce 2005, a bylo mu přisuzováno insulin mimetické působení. Dále bylo ukázáno, že visfatin má v organismu ještě další role – roli imunomodulačního cytokinu PBEF a enzymu nikotinamidfosforibosyltransferasy. Protože však prozatím nebyl nalezen receptor, na který by se visfatin vázal, ani nebyla objevena cesta jeho sekrece, zůstává otázkou, zda visfatin plní všechny úlohy které mu jsou přisuzovány.

Increasing incidence of obesity is one of the major challenges of the current global population. The most serious problem of obesity are accompanying complications, including insulin resistance and cardiovascular disorders. Recently was discovered new role of adipose tissue – secretion adipokines. Adipokines are tissue hormones which are involved in numerous regulatory processes. Visfatin has been described in 2005 as insulin mimetic adipokine. Furthermore, it was shown that visfatin has another role – the role of immunomodu - latory cytokine PBEF and enzyme nicotinamide phosphoribosyltransferase. But now there is question whether visfatin has all of these roles, because visfatins secretion pathway and visfatin receptor has not yet been found

• MeSH
• adipokiny * genetika   sekrece   MeSH
• nikotinamidfosforibosyltransferasa * fyziologie   chemie   MeSH
• nitrobřišní tuk imunologie   metabolismus   MeSH
• obezita * imunologie   metabolismus   MeSH
• tukové buňky imunologie   metabolismus   MeSH
• Publikační typ
• práce podpořená grantem MeSH

Dizertační práce, která se zaměřila na výzkum idiopatických zánětlivých myopatií a roli BAFF, interferonu alfa, visfatinu a autoprotilátek.

• MeSH
• autoprotilátky MeSH
• faktor aktivující B-buňky MeSH
• fenotyp MeSH
• imunologické testy MeSH
• interferon alfa MeSH
• messenger RNA MeSH
• myozitida MeSH
• nikotinamidfosforibosyltransferasa MeSH
• receptor faktoru aktivujícího B-buňky MeSH
• Publikační typ
• vysokoškolské kvalifikační práce MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• alergologie a imunologie
• ortopedie

AIMS: Visfatin (NAMPT/PBEF) is a recently identified adipocytokine which harbors strong insulin-mimetic activity and was reported to be associated with obesity. However, nothing is known about whether visfatin is related to specific nutritional behavior which may result in obesity development. This is the first study focusing on genetic variability of the visfatin gene and its association with circulating visfatin, anthropometric parameters and dietary composition. MATERIALS AND METHODS: We analyzed a total of 11 exons and adjacent non-coding regions of the NAMPT gene in 20 extremely obese Czech individuals (mean BMI 52.2±5.0 SD) using direct sequencing and a frequency of rs2302559 was established in the validation cohort of another 605 individuals with completed 7-day food records and complex anthropometric measurements. Serum levels of visfatin, leptin and leptin-receptor were measured in all sequenced individuals and in part of the validation cohort. RESULTS: Three common polymorphisms were identified, two in non-coding regions (rs78411774 A/C, rs71564769 A/C) and one synonymous SNP in exon 7 (rs2302559 A/G). The rs2302559 showed significant correlation with visfatin serum level throughout the entire study cohort (p<0.001); there was a significant tendency toward higher visfatin levels in G allele carriers with GG homozygotes having the highest visfatin serum levels. Furthermore, a negative correlation was observed between visfatin and leptin serum level (p=0.01). No association between investigated SNPs and anthropometric parameters or native dietary composition was observed. CONCLUSION: This is the first study to demonstrate that the rs2302559 polymorphism in the PBEF gene is related to circulating levels of visfatin. As the SNP is synonymous, we hypothesize it might be linked to another SNP in the PBEF gene which controls visfatin serum levels.

• MeSH
• antropometrie MeSH
• běloši genetika   MeSH
• cytokiny genetika   metabolismus   MeSH
• dieta * MeSH
• dietní záznamy MeSH
• hubenost MeSH
• index tělesné hmotnosti MeSH
• jednonukleotidový polymorfismus * MeSH
• krevní glukóza metabolismus   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nikotinamidfosforibosyltransferasa genetika   metabolismus   MeSH
• obezita epidemiologie   genetika   metabolismus   MeSH
• sekvenční analýza MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• validační studie MeSH
• Geografické názvy
• Česká republika MeSH

Visfatin, a product of PBEF gene, is an adipocytokine that harbours strong insulin-mimetic activity and it has been reported previously to associate with obesity. Recent reports also provide evidence that Visfatin has also important intracellular effects as it is homologous with nicotinamide phosphoribosyltransferase (NAMPT). In this review, we summarize the main documented effects of Visfatin on metabolism in humans, with special emphasis put on the pathways associated with obesity.

• MeSH
• beta-buňky metabolismus   MeSH
• cytokiny metabolismus   MeSH
• inzulinová rezistence * MeSH
• lidé MeSH
• lipidy krev   MeSH
• nikotinamidfosforibosyltransferasa metabolismus   farmakologie   MeSH
• obezita metabolismus   MeSH
• tuková tkáň metabolismus   MeSH
• zánět metabolismus   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

Endothelial activation and dysfunction may play a significant role in the progression of breast cancer. In our study we examined markers of endothelial activation (soluble ICAM-1, P-selectin, E-selectin) in 98 young patients with breast cancer (< 40 years). In 50 of them (and 20 age-matched controls) we also measured flow mediated vasodilation. Patients with breast cancer had significantly higher serum levels of soluble E-selectin, P-selectin and ICAM-1, P-selectin was higher in patients with larger tumors, node involvement and seemed to be a predictor of poor outcome. We were unable to find significant difference in the parameters of flow mediated vasodilation between patients with breast cancer and healthy subjects, although both peak blood flow (PBF) and flow mediated vasodilation (FMD) seemed to be skewed compared to healthy subjects toward mean and lower levels. Cluster analysis enabled us to distinguish several larger groups of patients with different degree of endothelial activation and function and different outcome. Group of patients with high E-selectin, high ICAM-1 (higher endothelial activation) and low VEGF (putative endothelial damage) had more frequently negative estrogen receptors and had worse outcome compared to the group of patients with lower E-selectin, lower ICAM-1 and mostly positive estrogen receptors. Further studies of larger groups of patients should help to identify the pannel of endothelial markers which could help in predicting the outcome of young patients with breast cancer.

• MeSH
• cévní endotel * metabolismus   patologie   MeSH
• dospělí MeSH
• E-selektin krev   MeSH
• ELISA MeSH
• lidé MeSH
• lokální recidiva nádoru MeSH
• lymfatické metastázy MeSH
• mezibuněčná adhezivní molekula-1 krev   MeSH
• míra přežití MeSH
• nádorové biomarkery krev   MeSH
• nádory prsu * komplikace   krev   mortalita   MeSH
• následné studie MeSH
• P-selektin krev   MeSH
• prognóza MeSH
• staging nádorů mortalita   MeSH
• studie případů a kontrol MeSH
• vaskulární endoteliální růstový faktor A krev   MeSH
• vazodilatace MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• práce podpořená grantem MeSH
• srovnávací studie MeSH

• MeSH
• lékařství MeSH
• studenti MeSH
• věda MeSH
• Publikační typ
• abstrakty MeSH
• kongresy MeSH
• sborníky MeSH

• Konspekt
• Lékařské vědy. Lékařství
• NLK Obory
• lékařství